OptiNose(OPTN) - 2023 Q2 - Earnings Call Presentation

| --- | --- | --- | |-------|-------|----------------------------------------------| | | | | | | | FDA accepted for review our supplemental new | optinose® Q2 2023 Performance XHANCE New Prescriptions increased 3%, Total Prescriptions increased 3% and HCPs who had a prescription filled by their patients increased 4% from Q2 2022 to Q2 2023 8 XHANCE Prescriptions – Second Quarter 2023 30.1 30.9 Q2 '22 Q2 '23 (in thousands) XHANCE New Prescriptions 87.7 90.7 Q2 '22 Q2 '23 XHANCE Total Prescriptions (in thousa ...